These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38356447)

  • 21. A focus on pharmacotherapy for primary central nervous system lymphoma.
    Korfel A
    Expert Rev Hematol; 2015 Oct; 8(5):559-62. PubMed ID: 26159859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
    Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C
    Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
    Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
    Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
    Wang A; Cirrone F; De Los Reyes FA; Papadopoulos J; Saint Fleur-Lominy S; Xiang E
    Leuk Lymphoma; 2022 Jun; 63(6):1348-1355. PubMed ID: 35120432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
    Fritsch K; Kasenda B; Schorb E; Hau P; Bloehdorn J; Möhle R; Löw S; Binder M; Atta J; Keller U; Wolf HH; Krause SW; Heß G; Naumann R; Sasse S; Hirt C; Lamprecht M; Martens U; Morgner A; Panse J; Frickhofen N; Röth A; Hader C; Deckert M; Fricker H; Ihorst G; Finke J; Illerhaus G
    Leukemia; 2017 Apr; 31(4):846-852. PubMed ID: 27843136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma.
    Fu J; Ma X
    J BUON; 2021; 26(2):366-372. PubMed ID: 34076981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab].
    Shiota Y; Dobashi N; Ito Y; Hosoba R; Yamauchi H; Ishii H; Nakano A; Fukushima R; Ohba R; Yahagi Y; Usui N; Yano S
    Rinsho Ketsueki; 2019; 60(2):87-92. PubMed ID: 30842385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
    Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
    Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
    [No Abstract]   [Full Text] [Related]  

  • 32. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
    Steinhardt MJ; Krummenast FC; Rosenwald A; Gerhard-Hartmann E; Heidemeier A; Einsele H; Topp MS; Duell J
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):205-214. PubMed ID: 34085097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.
    Nguyen DT; Houillier C; Choquet S; Cassoux N; Soussain C; Le Cossec C; Legarf-Tavernier M; Costopoulos M; LeHoang P; Bodaghi B; Omuro A; Hoang-Xuan K; Touitou V
    Ophthalmology; 2016 Sep; 123(9):2047-50. PubMed ID: 27137876
    [No Abstract]   [Full Text] [Related]  

  • 34. A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev).
    Cabanillas F; Rivera N; Acosta M; Pardo W; Solivan P; Rivera C; Liboy I
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):776-783. PubMed ID: 31591042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Options for Recurrent Primary CNS Lymphoma.
    Kaulen LD; Baehring JM
    Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
    Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
    Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
    [No Abstract]   [Full Text] [Related]  

  • 37. Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
    Gupta NK; Wang CC; Mannis GN; Yu JJ; Rubenstein JL
    Leuk Lymphoma; 2017 Nov; 58(11):2748-2751. PubMed ID: 28395565
    [No Abstract]   [Full Text] [Related]  

  • 38. [Curative Efficacy of High Dose MTX Combined with Rituxan for Treatment Primary CNS Lymphoma].
    Mou K; Gu WW; Gu CH; Qi JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1406-1409. PubMed ID: 29070115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of central nervous system malignant lymphoma].
    Nakamura O
    No To Shinkei; 2005 Dec; 57(12):1043-9. PubMed ID: 16375189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.